BioSpace News Archive

PsyRx is pleased to announce the successful conclusion of the live phase of a toxicological safety study involving the combined treatment of SSRI plus ibogaine.

Inspira Technologies today announced its financial results for the year ended December 31, 2023.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2nd tranche of its previously announced non-brokered private placement (the “Offering”) of units

Brain Trust Bio, a leader in treatment development for central nervous system diseases, has received approval to commence Phase I clinical trials in Australia for its Continuous Intrathecal Drug Delivery Method.

Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced landmark new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference being held virtually on April 8-9, 2024.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today provided a business update for the Company and presented financial results for the year ended December 31, 2023.

TFF Pharmaceuticals, Inc. today announced the acceptance of its late-breaking clinical science abstract for oral presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting.

A2 Biotherapeutics, Inc. today announced the appointment of James Robinson as its Chief Executive Officer and a member of its Board of Directors, effective April 1st , 2024.